<DOC>
	<DOCNO>NCT00362440</DOCNO>
	<brief_summary>The purpose study determine whether patient HIV lipodystrophy ( fat wasting ) benefit take combination two drug , one insulin sensitizer ( either metformin pioglitazone , diabetes drug ) leptin ( natural hormone produce fat cell ) . Our hope improve sugar fat metabolism positively affect body fat change notice take HAART .</brief_summary>
	<brief_title>Combination Insulin Sensitizer Leptin Treatment HAART -Induced Metabolic Syndrome</brief_title>
	<detailed_description>Highly active antiretroviral therapy ( HAART ) induce profound sustained suppression human immunodeficiency virus ( HIV ) replication , thus effective reduce disease-associated morbidity mortality patient population . However , HAART also result development lipodystrophic syndrome characterize fat accumulation , fat wasting , combination , similar congenital form lipodystrophy , associate component metabolic syndrome , include insulin resistance ( IR ) , fast hypertriglyceridemia , hypercholesterolemia . Our study `` proof concept '' study treatment HAART-induced metabolic syndrome , build upon represent direct extension study previously fund American Diabetes Association ( ADA ) . If clinical trial prove combination treatment leptin insulin sensitizer additive synergistic effect reverse metabolic abnormality HIV positive patient lipoatrophy , could lead design large multi-center , randomize , placebo-controlled trial ( ) aim establish safety efficacy treatment HAART-induced metabolic syndrome .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age18 year ability willingness give write informed consent Documented HIV1 infection At least 6 month stable cumulative antiretroviral therapy available investigational anti retroviral medication ( protease inhibitor , nucleoside reverse transcriptase inhibitor , nonnucleoside reverse transcriptase inhibitor , nucleotide reverse transcriptase inhibitor ) Lipoatrophy develop initiate HAART treatment ( see criterion ) . Leptin level less 4 ng/ml . Insulin resistance , impair fast glucose , impair glucose tolerance type 2 diabetes develop start antiretroviral medication . These category define , respectively , fast insulin level 15 ÂµIU/ml ; fast serum glucose value 100 mg/dl ; 2hour serum glucose level 75 gram oral glucose tolerance test ( OGTT ) 140 200 mg/dl ; fast glucose 126 mg/dl random glucose level 200 mg/dl presence classic symptom diabetes , polyuria , polydipsia , ketonuria , rapid weight loss Hypertriglyceridemia and/or hypercholesterolemia develop start antiretroviral therapy . These category define fast triglyceride great 150 mg/dl LDL cholesterol great 130 mg/dl , respectively Female subject must negative urine pregnancy test enrollment must agree use barrier contraception i.e . condom , diaphragm IUD , without hormonalbased method duration study . Women pregnant become pregnant study accept form contraception exclude study . Patients history peripheral fat waste face ( e.g . sunken cheek ) , limb ( include prominent vein ) , and/or buttock , develop initiation HAART therapy Patients physical exam finding ) facial atrophy sunken cheek , sunken temporal region , and/or prominent temporal vein b ) waste fat periphery , limbs and/or buttock ( include prominent vein ) Patients anthropometric measurement suggestive decrease subcutaneous fat content : Decreased triceps skinfold thickness ( &lt; 4 mm men &lt; 8 mm woman ) Decreased upper arm circumference ( &lt; 27.1 cm men &lt; 23.3 cm woman ) Decreased subscapular skinfold thickness ( &lt; 7 mm men &lt; 7 mm woman ) dual energy Xray absorptiometry ( DEXA ) scan suggestive fat depletion : total body fat &lt; 14 % men &lt; 22 % woman . History impair glucose metabolism hyperlipidemia prior antiretroviral use Triglyceride level higher 1500 mg/dl 1 month runin phase anytime study Abnormal hepatic function : liver function test higher twice upper normal range Abnormal renal function : creatinine high 1.3 mg/dl Any condition/illness may affect study outcomes pregnancy , active infection except HIV , clinically significant malabsorption/malnutrition , malignancy Any active hormonal disease and/or hormonal treatment may affect outcomes interest clinically overt hypo/hyperthyroidism , hypogonadism , hypercortisolism , treatment steroid growth hormone ( exception : patient take testosterone include trial agree continue dosage duration trial ) Present alcoholism drug abuse . These condition screen detailed history system review baseline laboratory analysis chemistry , CBC , hormone level , EKG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV lipodystrophy</keyword>
	<keyword>Leptin</keyword>
	<keyword>Fat waste</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>